Angiotensin Ii — Competitive Intelligence Brief

Angiotensin Ii (ANGIOTENSIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasoconstrictor [EPC]. Area: Hematology.

marketed Vasoconstrictor [EPC] Hematology Recombinant protein

Target snapshot

Angiotensin Ii (ANGIOTENSIN) — La Jolla Pharma. Angiotensin II works by binding to its receptor, triggering a cascade of signals that ultimately lead to the constriction of blood vessels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Angiotensin Ii TARGET	ANGIOTENSIN	La Jolla Pharma	marketed	Vasoconstrictor [EPC]		2025-01-01
Giapreza	ANGIOTENSIN II	La Jolla Pharma	marketed	Vasoconstrictor [EPC]	Type-2 angiotensin II receptor, Type-1 angiotensin II receptor, Type-1 angiotensin II receptor	2017-01-01
lidocaine + epinephrine 1:100,000	lidocaine + epinephrine 1:100,000	Weill Medical College of Cornell University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels (lidocaine); alpha-1 and beta-1 adrenergic receptors (epinephrine)
tetracaine HCl and oxymetazoline HCL	tetracaine HCl and oxymetazoline HCL	Louisiana State University Health Sciences Center in New Orleans	marketed	Local anesthetic with vasoconstrictor combination	Voltage-gated sodium channels (tetracaine); alpha-2 adrenergic receptors (oxymetazoline)
Tumescent Solution with dilute epinephrine	Tumescent Solution with dilute epinephrine	University of Wisconsin, Madison	marketed	Local anesthetic with vasoconstrictor
Ropivicaine with Epinephrine	Ropivicaine with Epinephrine	Health Sciences North Research Institute	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels
Levobupivacaine with epinephrine	Levobupivacaine with epinephrine	Pontificia Universidad Catolica de Chile	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasoconstrictor [EPC] class)

1. La Jolla Pharma · 2 drugs in this class